Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.
The addition of androgen deprivation therapy (ADT) to definitive external beam radiation therapy (RT) improves outcomes in higher-risk prostate cancer patients. However, the benefit of ADT with salvage RT in post-prostatectomy patients is not clearly established. Our study compares biochemical outcomes in post-prostatectomy patients who received salvage RT with or without concurrent ADT.
Of nearly 2,000 post-prostatectomy patients, we reviewed the medical records of 191 patients who received salvage RT at the University of Pennsylvania between 1987 and 2007. Follow-up data were obtained by chart review and electronic polling of the institutional laboratory database and Social Security Death Index. Biochemical failure after salvage RT was defined as a prostate-specific antigen of 2.0 ng/mL above the post-RT nadir or the initiation of ADT after completion of salvage RT.
One hundred twenty-nine patients received salvage RT alone, and 62 patients received combined ADT and salvage RT. Median follow-up was 5.4 years. Patients who received combined ADT and salvage RT were younger, had higher pathologic Gleason scores, and higher rates of seminal vesicle invasion, lymph node involvement, and pelvic nodal irradiation compared with patients who received salvage RT alone. Patients who received combined therapy had improved biochemical progression-free survival (bPFS) compared with patients who received RT alone (p = 0.048). For patients with pathologic Gleason scores ≤7, combined RT and ADT resulted in significantly improved bPFS compared to RT alone (p = 0.013).
These results suggest that initiating ADT during salvage RT in the post-prostatectomy setting may improve bPFS compared with salvage RT alone. However, prospective randomized data are necessary to definitively determine whether hormonal manipulation should be used with salvage RT. Furthermore, the optimal nature and duration of ADT and the patient subgroups in which ADT could provide the most benefit remain open questions.
雄激素剥夺治疗(ADT)联合根治性外束放射治疗(RT)可改善高危前列腺癌患者的预后。然而,在前列腺切除术患者中,挽救性 RT 联合 ADT 的获益尚不清楚。本研究比较了在宾夕法尼亚大学接受挽救性 RT 治疗的前列腺切除术患者中,接受或不接受同期 ADT 治疗的生化结局。
在近 2000 例前列腺切除术患者中,我们回顾了 191 例于 1987 年至 2007 年期间在宾夕法尼亚大学接受挽救性 RT 的患者的病历。通过图表回顾和机构实验室数据库及社会安全死亡索引的电子投票获取随访数据。挽救性 RT 后生化失败定义为 PSA 水平在 RT 后最低点之上 2.0ng/ml 或完成挽救性 RT 后开始 ADT。
129 例患者接受单纯挽救性 RT,62 例患者接受 ADT 联合挽救性 RT。中位随访时间为 5.4 年。与单纯接受挽救性 RT 的患者相比,接受 ADT 联合挽救性 RT 的患者年龄更小,病理 Gleason 评分更高,精囊侵犯、淋巴结受累和盆腔淋巴结照射的发生率更高。与单纯接受 RT 的患者相比,接受联合治疗的患者生化无进展生存期(bPFS)有改善(p=0.048)。对于病理 Gleason 评分≤7 的患者,联合 RT 和 ADT 可显著改善 bPFS(p=0.013)。
这些结果表明,与单纯挽救性 RT 相比,在前列腺切除术患者中,挽救性 RT 期间开始 ADT 可能改善 bPFS。然而,需要前瞻性随机数据来明确确定挽救性 RT 是否应联合激素治疗。此外,ADT 的最佳性质和持续时间以及 ADT 最能获益的患者亚组仍然是悬而未决的问题。